|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Audentes_Therapeutics
gptkb:Iveric_Bio
gptkb:Mitobridge
|
|
gptkbp:annualReport
|
https://www.astellas.com/en/investors/ir-library/annual-reports
|
|
gptkbp:category
|
gptkb:conglomerate
gptkb:public_company
Japanese brand
life sciences company
|
|
gptkbp:CEO
|
gptkb:Naoki_Okamura
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:formedByMergerOf
|
gptkb:Fujisawa_Pharmaceutical
gptkb:Yamanouchi_Pharmaceutical
|
|
gptkbp:founded
|
2005
|
|
gptkbp:headquarters_location
|
gptkb:Tokyo
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
JP3942400007
|
|
gptkbp:languageOfService
|
English
Japanese
|
|
gptkbp:listedOn
|
gptkb:Nikkei_225
|
|
gptkbp:logo
|
Astellas_Pharma_logo.svg
|
|
gptkbp:market
|
global
|
|
gptkbp:member
|
gptkb:Japan_Pharmaceutical_Manufacturers_Association
|
|
gptkbp:notableProduct
|
gptkb:Betanis
gptkb:Prograf
gptkb:Vesicare
gptkb:Xtandi
|
|
gptkbp:numberOfEmployees
|
~15,000
|
|
gptkbp:parentCompany
|
gptkb:Astellas_Holdings
|
|
gptkbp:products
|
oncology drugs
immunology drugs
transplantation drugs
urology drugs
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:researchInterest
|
immunology
infectious diseases
oncology
transplantation
urology
|
|
gptkbp:revenue
|
1.5 trillion yen (2023)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:ALPMY
4503
|
|
gptkbp:subsidiary
|
gptkb:Astellas_Pharma_Europe_Ltd.
gptkb:Astellas_US_LLC
|
|
gptkbp:website
|
https://www.astellas.com/
|
|
gptkbp:bfsParent
|
gptkb:Frequency_Therapeutics
|
|
gptkbp:bfsLayer
|
4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Astellas Pharma
|